20 citations
,
August 2019 in “Frontiers in immunology” This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
4 citations
,
May 2025 in “Clinical & Experimental Allergy” This study confirmed omalizumab's safety but noted that hair loss was more prevalent than previously reported, with side effects influencing treatment decisions especially in patients with reduced medication effectiveness.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.
June 2025 in “Frontiers in Medicine” This study observed that omalizumab may induce alopecia, particularly in females aged 18-60, though establishing a direct cause-effect link remains challenging. Alopecia areata was noted as a possible uncommon, yet transient, hair loss type associated with omalizumab.